FLT3 and acute myeloid leukemia: Another study evaluated azacitidine or low-dose cytarabine (LDAC) in combination with quizartinib in patients with FLT3-ITD-mutated AML, including patients with relapsed/refractory disease or newly diagnosed patients who were >60 years of age and/or considered to be unfit for intensive chemotherapy [42].